查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863442

多癌种筛检市场按检测类型、癌症类型、技术、支付方式、应用和最终用户划分－2025-2032年全球预测

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，多癌种筛检市场将成长至 33.6 亿美元，复合年增长率为 10.31%。

关键市场统计数据
基准年 2024 15.3亿美元
预计年份：2025年 16.7亿美元
预测年份 2032 33.6亿美元
复合年增长率 (%) 10.31%

本文全面概述了多癌种筛检的进步如何改变临床实践、研究重点以及诊断和治疗路径中的相关人员合作。

分子生物学、生物资讯学和检体采集技术的进步正汇聚一堂，推动多癌种筛检领域从实验阶段走向临床和研究的实际应用。新的诊断方法正在重塑检测模式，从微创检体到更广泛的组织覆盖，从而改变临床工作流程和患者诊疗路径。因此，诊断开发、医疗服务和政策制定领域的利益相关人员正在重新评估早期检测、长期监测和循证医学证据产生的优先事项，以支持临床应用。

临床实验室和研发人员正面临来自科学和营运两方面的压力：既要平衡分析灵敏度和特异性，也要兼顾通量、成本和监管合规性。同时，支付方和医疗系统也要求提供明确的临床效用证据，以及将积极发现融入临床观察的可行路径。在此背景下，转化研究和务实的临床试验正成为生物标记发现与常规应用之间的关键桥樑，有助于明确合适的应用场景、转诊网路和路径经济性，从而实现负责任的规模化应用。因此，现在就投资于可靠的临床检验、互通性和相关人员协作的机构，有望加速可靠应用并产生长期影响。

技术、临床和支付方的发展趋势相互交汇，重新定义了多癌症种筛检创新技术的研发重点和推广路径。

技术变革、数据整合以及报销理念的转变正在颠覆整个多筛检格局。在技​​术层面，液态生物检体、高通量定序和多重检测的创新正在拓展可检测分析物的范围，并降低非侵入性取样的门槛。这些技术进步伴随着生物资讯学流程的改进，提高了讯号检测的准确性，降低了假阳性噪声，从而能够提供更多具有临床指导意义的结果。

在系统层面，医疗模式正朝着整合式医疗模式转变，将筛检结果与标准化的诊断追踪和治疗路径连结起来。这种整合得益于可互通的数据标准和电子健康记录的互联互通，使筛检结果能够及时驱动临床回应。同时，支付方的讨论也从单一疾病检测的单一报销模式，转向以价值为导向的框架，该框架考虑长期效益和后续的医疗协调。因此，相关人员在调整产品开发策略、临床证据计画和商业化蓝图，以适应这些变革，并确保临床和商业性路径的永续。

评估美国关税政策波动如何影响诊断相关人员的供应链韧性、筹资策略和製造在地化决策。

关税政策变化和贸易行动将对用于多癌种筛检的试剂、仪器和客製化检测组件的全球供应链产生重大影响。在美国，关税制度的变化会影响定序试剂、质谱耗材和专用硬体等关键材料的到岸成本，进而影响实验室和诊断开发人员的采购策略。这些成本压力促使他们更加重视国内采购、策略供应商合作以及库存管理技术，以维持检测服务的连续性。

除了成本影响外，关税正在加速策略性製造地决策和关键流程的在地化，促使企业考虑地理分散式供应链和近岸外包方案。风险缓解策略正推动一些机构增加对国内契约製造的投资，签订分包协议，并加强供应商资格认证计画。同时，采购部门和实验室营运人员正在加强情境规划，以应对短期价格波动，同时确保检测效能和合规性。最终，关税政策的变化既是对营运的压力测试，也是推动供应链韧性策略与长期临床服务目标一致的促进者。

综合細項分析揭示了检测类型、癌症标靶、技术、支付方式、应用和最终用户如何共同影响检测的普及和临床效用。

細項分析突显了技术方法、临床标靶、支付模式和终端用户在多筛检路径中的多样性。按检测类型划分，目前的服务产品涵盖范围广泛，从针对特定基因组区域的基因panel检测，到经认证实验室定制的实验室自建检测（LDT），再到液态生物检体领域也十分多样，包括乳癌和大肠癌等成熟标靶，白血病等骨髓恶性肿瘤，肺癌等高负担疾病，以及广泛的特异性多器官癌症检测模式，还有摄护腺癌等筛检特异性标靶。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 人工智慧驱动的液态生物检体检测在多种癌症早期检测中的应用日益广泛
  • 监管核准流程影响下一代多癌症筛检测试的商业化进程
  • 增加对cfDNA甲基化检测板的投资正在提高检测的灵敏度和特异性。
  • 透过诊断实验室与科技公司之间的合作，加速多癌种筛检创新
  • 消费者多癌种筛检套件的广泛普及，使得在家检体样本即可进行早期诊断。
  • 整合电子健康记录数据和筛检结果，以支持个人化癌症风险模型
  • 基于价值的报销模式的出现正在影响医疗系统中多种癌症筛检的普及。
  • 重点关注医疗服务不足的人群，以促进在低收入地区开展便利的多癌种筛检计画。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按检测类型分類的多癌种筛检市场

  • 基因检测
  • 实验室自建测试
  • 液态生物检体

第九章 依癌症类型分類的多癌症种筛检市场

  • 乳癌
  • 大肠直肠癌
  • 白血病
  • 肺癌
  • 特异性多重器官癌
  • 摄护腺癌

第十章 以科技分類的多癌症种筛检市场

  • 质谱分析
  • 微阵列
  • 次世代定序
  • 聚合酵素链锁反应

11. 依支付方式分類的多癌种筛检市场

  • 政府补贴
  • 自费
  • 私人医疗保险

第十二章 多癌种筛检市场（依应用领域划分）

  • 诊断筛检
    • 早期检测
    • 风险评估
  • 预后
    • 病患监测
    • 治疗方法方案
    • 治疗效果评估
  • 研究用途
    • 生物标记发现
    • 基因研究

第十三章 依最终用户分類的多癌症种筛检市场

  • 门诊手术中心
  • 诊断中心
  • 医院
  • 研究所
  • 专科诊所

第十四章 各地区多元癌症筛检市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 依组别分類的多癌症种筛检市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国多癌症种筛检市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • ANPAC Bio-Medical Science Co., Ltd.
    • Burning Rock Biotech Limited
    • Caris Life Sciences
    • Coyne Medical Ltd.
    • Delfi Diagnostics, Inc.
    • Elypta AB
    • EpiCypher, Inc.
    • Epigenomics AG
    • Exact Sciences Corporation
    • Foundation Medicine, Inc.
    • Freenome Holdings, Inc.
    • Fulgent Genetics, Inc.
    • Gene Solutions
    • Grail, LLC by Illumina, Inc.
    • Guangzhou AnchorDx Medical Co., Ltd.
    • Guardant Health, Inc.
    • Invitae Corporation
    • Laboratory Corporation of America Holdings
    • Lucence Health Inc.
    • Micronoma, Inc.
    • MiRXES Pte Ltd.
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • Naveris, Inc.
    • NeoGenomics Laboratories
    • OneTest
    • Siemens Healthineers AG
    • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market is projected to grow by USD 3.36 billion at a CAGR of 10.31% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.53 billion
Estimated Year [2025] USD 1.67 billion
Forecast Year [2032] USD 3.36 billion
CAGR (%) 10.31%

A compelling overview of how multicancer screening advances are shifting clinical practice, research priorities, and stakeholder collaboration across diagnostics and care pathways

The field of multicancer screening is evolving from experimental promise to pragmatic integration within clinical and research settings, driven by converging advances in molecular biology, bioinformatics, and sample collection technologies. Emerging diagnostic modalities are reframing detection paradigms by offering broader tissue coverage from minimally invasive samples, thereby reshaping clinical workflows and patient pathways. As a result, stakeholders across diagnostics development, healthcare delivery, and policy are reevaluating priorities around early detection, longitudinal monitoring, and evidence generation to sustain clinical adoption.

Clinical laboratories and developers are responding to both scientific and operational pressures: they must balance analytical sensitivity and specificity with throughput, cost, and regulatory compliance. Concurrently, payers and health systems are seeking clearer proof of clinical utility and actionable pathways to integrate positive findings into care. In this environment, translational research and pragmatic trials are emerging as critical bridges between biomarker discovery and routine use, helping to define appropriate use cases, referral networks, and pathway economics that enable responsible scale-up. Consequently, organizations that invest now in robust clinical validation, interoperability, and stakeholder alignment stand to accelerate credible adoption and long-term impact.

How converging technological, clinical, and payer evolutions are redefining development priorities and adoption pathways in multicancer screening innovation

Transformations in technology, data integration, and reimbursement thinking are producing a set of disruptive shifts across the multicancer screening landscape. On the technology front, innovations in liquid biopsy, high-throughput sequencing, and multiplexed assays are expanding the range of detectable analytes and lowering the barrier to noninvasive sampling. These technical gains are accompanied by enhanced bioinformatic pipelines that improve signal detection and reduce false positive noise, enabling more clinically actionable outputs.

At the systems level, there is a move toward integrated care models that link screening results to standardized diagnostic follow-up and treatment pathways. This integration is facilitated by interoperable data standards and electronic health record connectivity that allow screening outcomes to trigger timely clinical responses. Simultaneously, payer discussions are evolving from unitary reimbursement for single-disease tests toward value frameworks that consider longitudinal benefit and downstream care coordination. As a result, stakeholders are recalibrating product development strategies, clinical evidence plans, and commercialization roadmaps to align with these transformative shifts and to secure sustainable clinical and commercial pathways.

Assessing how shifting US tariff policies are influencing supply chain resilience, procurement strategies, and manufacturing localization decisions for diagnostic stakeholders

Tariff policy changes and trade measures can exert meaningful influence on global supply chains for reagents, instruments, and bespoke assay components used in multicancer screening. In the United States, shifts in tariff regimes affect the landed cost of critical inputs such as sequencing reagents, mass spectrometry consumables, and specialized hardware, which in turn influence procurement preferences among laboratories and diagnostic developers. These cost pressures encourage greater attention to domestic sourcing, strategic supplier partnerships, and inventory management practices to maintain continuity of testing services.

Beyond cost considerations, tariffs can accelerate strategic decisions about manufacturing footprint and localization of critical production steps, prompting firms to evaluate regionalized supply chains and nearshoring options. For some organizations, this translates into increased investments in domestic contract manufacturing, secondary sourcing contracts, and supplier qualification programs to mitigate exposure. In parallel, procurement teams and laboratory operators are intensifying scenario planning to absorb short-term pricing volatility while preserving assay performance and regulatory compliance. Ultimately, tariff dynamics serve as both an operational stress test and a catalyst for supply chain resilience strategies that align with long-term clinical service objectives.

Integrated segmentation insights that reveal how test type, cancer target, technology, payment source, application, and end user collectively shape adoption and clinical utility

Segmentation analysis highlights the diversity of technological approaches, clinical targets, payment models, and end users that shape multicancer screening pathways. Based on test type, contemporary offerings range from gene panel approaches that target defined genomic regions to laboratory developed tests that are tailored within certified labs, and to liquid biopsy methods that leverage circulating analytes for minimally invasive sampling. Based on cancer type, the screening landscape spans established targets such as breast cancer and colorectal cancer, hematologic malignancies like leukemia, high-burden indications such as lung cancer, broad non-specific multi-organ cancer detection paradigms, and organ-specific targets like prostate cancer.

Based on technology, core platforms include mass spectrometry for proteomic signatures, microarray approaches for targeted genomic profiling, next-generation sequencing for comprehensive genomic and epigenomic interrogation, and polymerase chain reaction techniques for focused, high-sensitivity detection. Based on payment source, funding and access pathways vary with government subsidies that support public health initiatives, out-of-pocket payment for direct-to-consumer or elective services, and private health insurance that evaluates clinical utility and cost-effectiveness criteria. Based on application, offerings cover diagnostic screening for early detection and risk assessment, prognostic uses such as patient monitoring, therapy selection, and treatment efficacy assessment, and research applications including biomarker discovery and genetic research. Based on end user, deployment spans ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, each with distinct operational constraints, specimen logistics, and reporting requirements. Together, these segmentation lenses underscore the need for tailored evidence generation, commercial strategies, and implementation pathways that align with the intended use case and stakeholder expectations.

Comparative regional insights highlighting how regulatory frameworks, payer models, and healthcare infrastructure drive differentiated adoption pathways across global regions

Regional dynamics exert a pronounced influence on adoption pathways, regulatory expectations, and payer engagement for multicancer screening programs. In the Americas, mature healthcare infrastructures, active private payer markets, and strong translational research networks create an environment where commercial pilots and commercial models can advance rapidly, while regulatory oversight and reimbursement discussions focus on demonstrating clinical utility and care pathway integration. In Europe, Middle East & Africa, regulatory harmonization initiatives, variable reimbursement environments, and diverse healthcare delivery settings require adaptable evidence strategies, localized health economic models, and targeted stakeholder engagement to secure uptake.

In the Asia-Pacific region, rapid investments in sequencing capacity, growing public health screening initiatives, and expanding clinical trial activity are driving a dynamic landscape where both domestic innovators and global players pursue partnership models. Each region presents distinct operational considerations: supply chain logistics and laboratory capacity differ across geographies, payer frameworks range from public program-driven funding to mixed private-public arrangements, and clinician awareness and care pathways vary by local practice patterns. Consequently, commercial and clinical strategies must be regionally calibrated to address regulatory nuance, reimbursement pathways, and operational readiness while leveraging local research collaborations to accelerate evidence generation.

How collaboration, platform differentiation, and evidence-driven positioning are shaping competitive strategies and commercial pathways among diagnostic developers and laboratories

Competitive dynamics in the multicancer screening arena are characterized by a mix of established diagnostic manufacturers, specialized clinical laboratories, and nimble biotechnology startups pursuing differentiated scientific approaches. Many established players are expanding assay portfolios and forging partnerships with clinical networks to validate broader screening applications, while specialized laboratories are refining workflow integration and accreditation to support laboratory-developed tests with rapid iteration. Startups often focus on unique biomarker platforms, novel bioinformatics, or sample collection innovations that address specific gaps in sensitivity, specificity, or usability.

Strategic activity increasingly centers on collaboration: partnerships between technology providers and large laboratory networks enable access to diverse clinical specimens and pragmatic validation pathways, while alliances with academic centers facilitate translational studies and clinical utility evidence. In addition, contract development and manufacturing relationships help firms scale assay production, and collaborations with health systems support pilot implementations that test real-world clinical pathways. Across these dynamics, robustness of evidence, regulatory clarity, and the ability to integrate into clinical workflows remain primary differentiators that influence adoption trajectories and commercial positioning.

Practical, evidence-focused recommendations for developers, laboratories, and health systems to accelerate credible adoption and operational resilience in multicancer screening

Industry leaders can accelerate responsible adoption of multicancer screening by aligning product development with clear clinical use cases, prioritizing analytic rigor, and engaging early with payers and providers. First, define targeted clinical pathways that specify how a positive screening result will be triaged, what confirmatory diagnostics are required, and how follow-up care will be coordinated; clarity on downstream actions strengthens clinical utility arguments. Second, invest in analytical validation and reproducibility across diverse specimen types and demographic cohorts to reduce variability and build clinician confidence. Third, initiate payer dialogues early and develop health economic models that reflect realistic care pathways and patient journeys to inform reimbursement negotiations.

Operationally, leaders should pursue supply chain diversification and quality-controlled manufacturing to mitigate tariff and logistics risks while ensuring consistent test availability. In parallel, prioritize interoperable reporting formats and EHR integration to facilitate clinical decision support and reduce friction in provider workflows. From a commercialization perspective, pilot programs with integrated care partners, accompanied by pragmatic outcome measurement, provide actionable evidence that accelerates adoption. Finally, cultivate transparent communication with regulators and clinical societies to align on evidence thresholds and appropriate use cases, enabling scalable and clinically responsible deployment.

A rigorous mixed-methods research framework combining expert interviews, peer-reviewed evidence, regulatory review, and data triangulation to validate multicancer screening insights

The research approach combined multi-source evidence collection, expert validation, and iterative synthesis to produce balanced, actionable insights. Primary research included structured interviews with clinicians, laboratory directors, health economists, and payers to capture operational constraints, evidence expectations, and decision drivers across clinical settings. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory filings, and publicly available guidance from health technology assessment bodies to map technological capabilities and policy trends. Data triangulation was used to reconcile differing perspectives and to identify consistent signals across sources.

Analytical rigor was ensured by cross-checking technical claims against independent validation studies and by assessing operational feasibility through conversations with laboratory operators and supply chain experts. Key limitations and evidence gaps were explicitly characterized to inform future research priorities. Throughout the methodology, ethical considerations and data privacy practices guided the handling of any proprietary or patient-level information, and quality assurance steps were applied to maintain accuracy and credibility in the synthesis of findings.

Concluding synthesis emphasizing evidence alignment, operational readiness, and multi-stakeholder collaboration as prerequisites for responsible multicancer screening adoption

Multicancer screening is at an inflection point where technical maturity, clinical integration needs, and evolving payer perspectives converge to shape near-term trajectories. While technological advances are enabling broader and less invasive detection capabilities, sustainable adoption depends on demonstrable clinical pathways, interoperable reporting, and aligned reimbursement approaches. Stakeholders that pursue clear use case definition, robust validation across diverse cohorts, and pragmatic collaborations with care networks will be best positioned to translate innovation into measurable clinical benefit.

Looking ahead, the focus will be on closing evidence gaps around clinical utility, refining operational models to support scalable testing, and building resilient supply chains that accommodate changing trade and procurement landscapes. By emphasizing transparency in performance, fostering multi-stakeholder engagement, and investing in interoperable systems, the field can progress toward screening programs that deliver earlier detection, more personalized care, and improved outcomes for patients while ensuring sustainable implementation within health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of AI-driven liquid biopsy assays for early multicancer detection
  • 5.2. Regulatory approval pathways shaping commercialization of next-generation multicancer screening tests
  • 5.3. Rising investment in cfDNA methylation panels enhancing sensitivity and specificity of tests
  • 5.4. Partnerships between diagnostic labs and technology firms accelerating multicancer screening innovation
  • 5.5. Expansion of direct-to-consumer multicancer screening kits enabling at-home sample collection for early diagnosis
  • 5.6. Integration of electronic health records data with screening results to support personalized cancer risk models
  • 5.7. Emergence of value-based reimbursement models influencing adoption of multicancer screening in health systems
  • 5.8. Focus on underserved populations driving development of accessible multicancer detection programs in low-income regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multicancer Screening Market, by Test Type

  • 8.1. Gene Panel
  • 8.2. Laboratory Developed Test
  • 8.3. Liquid Biopsy

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Leukemia
  • 9.4. Lung Cancer
  • 9.5. Non-Specific Multi-Organ Cancer
  • 9.6. Prostate Cancer

10. Multicancer Screening Market, by Technology

  • 10.1. Mass Spectrometry
  • 10.2. Microarray
  • 10.3. Next - Generation Sequencing
  • 10.4. Polymerase Chain Reaction

11. Multicancer Screening Market, by Payment Source

  • 11.1. Government Subsidies
  • 11.2. Out-of-Pocket Payment
  • 11.3. Private Health Insurance

12. Multicancer Screening Market, by Application

  • 12.1. Diagnostic Screening
    • 12.1.1. Early Detection
    • 12.1.2. Risk Assessment
  • 12.2. Prognostics
    • 12.2.1. Patient Monitoring
    • 12.2.2. Therapy Selection
    • 12.2.3. Treatment Efficacy Assessment
  • 12.3. Research Applications
    • 12.3.1. Biomarker Discovery
    • 12.3.2. Genetic Research

13. Multicancer Screening Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Diagnostic Centers
  • 13.3. Hospitals
  • 13.4. Research Institutions
  • 13.5. Specialty Clinics

14. Multicancer Screening Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Multicancer Screening Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Multicancer Screening Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. ANPAC Bio-Medical Science Co., Ltd.
    • 17.3.2. Burning Rock Biotech Limited
    • 17.3.3. Caris Life Sciences
    • 17.3.4. Coyne Medical Ltd.
    • 17.3.5. Delfi Diagnostics, Inc.
    • 17.3.6. Elypta AB
    • 17.3.7. EpiCypher, Inc.
    • 17.3.8. Epigenomics AG
    • 17.3.9. Exact Sciences Corporation
    • 17.3.10. Foundation Medicine, Inc.
    • 17.3.11. Freenome Holdings, Inc.
    • 17.3.12. Fulgent Genetics, Inc.
    • 17.3.13. Gene Solutions
    • 17.3.14. Grail, LLC by Illumina, Inc.
    • 17.3.15. Guangzhou AnchorDx Medical Co., Ltd.
    • 17.3.16. Guardant Health, Inc.
    • 17.3.17. Invitae Corporation
    • 17.3.18. Laboratory Corporation of America Holdings
    • 17.3.19. Lucence Health Inc.
    • 17.3.20. Micronoma, Inc.
    • 17.3.21. MiRXES Pte Ltd.
    • 17.3.22. Myriad Genetics, Inc.
    • 17.3.23. Natera, Inc.
    • 17.3.24. Naveris, Inc.
    • 17.3.25. NeoGenomics Laboratories
    • 17.3.26. OneTest
    • 17.3.27. Siemens Healthineers AG
    • 17.3.28. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE MULTICANCER SCREENING MARK